Latest News
Precision Biosciences initiates patient enrollment in PBGENE-DMD clinical study
29 April 2026 - Gene editing company Precision BioSciences Inc (Nasdaq:DTIL) reported on Wednesday that it has activated the first clinical trial site and commenced patient enrollment in its Phase 1/2 FUNCTION-DMD study evaluating PBGENE-DMD, an in v...
Immunome submits FDA application for varegacestat following strong Phase 3 results
29 April 2026 - Biotechnology company Immunome Inc (Nasdaq:IMNM) disclosed on Wednesday that it has submitted a New Drug Application to the U.S. Food and Drug Administration for varegacestat, an oral gamma secretase inhibitor for the treatment of adu...
HUTCHMED secures priority review for sovleplenib NDA in China
29 April 2026 - Biopharmaceutical company HUTCHMED (China) Limited (Nasdaq:HCM) (AIM:HCM) (HKEX:13) announced on Wednesday that the New Drug Application for sovleplenib has been accepted for review and granted priority status by the China National Me...
Chiesi Group to acquire KalVista Pharmaceuticals for USD1.9bn in rare disease expansion strategy
29 April 2026 - Chiesi Group, an international research-focused biopharmaceutical group and certified B Corp, announced on Wednesday that it has entered into a definitive agreement to acquire biopharmaceutical company KalVista Pharmaceuticals Inc (Na...
European Commission clears first pertuzumab biosimilar in Europe
29 April 2026 - China-based biopharmaceutical company Shanghai Henlius Biotech Inc (HK:2696) and US healthcare company Organon (NYSE:OGN) announced on Wednesday that the European Commission has approved POHERDY (pertuzumab), the first biosimilar to P...